Bacteria-targeted MSNs as antimicrobial delivery systems.
| Targeting liganda | Bacteriab | Drug loadedc | Nanocarrierd | Assay | Ref. |
|---|---|---|---|---|---|
| FB11 | F. tularensis | Model drugs (Fluorescein, Hoechst 33342) | MCM-41 FB11mFt LPS-MSNs | In vitro | 529 |
| Anti-S. aureus Ab | S. aureus | Vancomycin | Ab@S-HA@MMSNs | In vitro | 714 |
| SA20hp | S. aureus | Vancomycin | MCM-41 SA20hp-MSNs | In vitro | 715 |
| UBI29–41 | S. aureus | Gentamicin | MSN-LU | In vitro and in vivo | 716 |
| LL-37 | P. aeruginosa | Colistin | MSN@LL-(LL-37) | In vitro | 717 |
| Trehalose | M. smegmatis | Isoniazid | M-PFPA-Tre | In vitro | 718 |
| Trehalose | M. smegmatis | Isoniazid | Tre-HOMSNs | In vitro | 719 |
| Arginine | S. typhimurium | Ciprofloxacin | Arg-MSNs | In vitro and in vivo | 720 |
| Folic acid | E. coli, S. aureus | Ampicillin | MSN@FA@CaP@FA | In vitro and in vivo | 721 |
| Vancomycin | S. aureus | Vancomycin (grafted) | MCM-41 MSNs⊂VAN | In vitro | 722 |
| OMV | E. coli | Rifampicin | OMV@MSN | In vitro and in vivo | 723 |
| ε-pLys | E. coli, S. typhi, E. Carotovora | Vancomycin | MCM-41 ε-pLys-MSNs | In vitro | 724 |
| ε-pLys | E. coli, S. marcescens | HKAIs | MCM-41 ε-pLys-MSNs | In vitro and in vivo | 725 |
| LYS | E. coli, B. safensis | KANA | MSN–AuNC@LYS | In vitro | 726 |
| G3 | E. coli | Levofloxacin | MCM-41 G3-MSNs | In vitro | 727 |
| G3 | E. coli | Levofloxacin | MCM-41 Mn+-G3-MSNs | In vitro | 625 |
FB11: FB11 antibody for lipopolysaccharide (LPS) present in Francisella tularensis (Ft); Anti-S. aureus: S. aureus antibody; SA20hp: SA20 aptamer with hairpin structure; UBI29–41: Ubiquicin; LL-37 peptide: human cathelicidin peptide; Arg: arginine; OMV: outer membrane vesicle isolated from E. coli; ε-pLys: ε-poly-l-lysine cationic polymer; LYS: lysozyme, and G3: poly(propyleneimine) third-generation dendrimer.
E. coli: Escherichia coli; S. marcescens: Staphylococcus marcescens; F. tularensis: Francisella tularensis; S. aureus: Staphylococcus aureus; P. aeruginosa: Pseudomonas aeruginosa; M. smegmatis: Mycobacterium smegmatis; S. typhi: Salmonella typhimurium; E. carotovora: Erwinia carotovora; and B. safensis: Bacillus safensis.
HKAIs: histidine kinase authophosphorylation inhibitors; and KANA: Kanamycin.
MCM-41 FB11mFt LPS-MSNs: MCM-41 type MSNs functionalized with FB11 antibody through a derivative of the O-antigen of Ft LPS; Ab@S-HA@MMSNs: sulfonated-hyaluronic acid (S-HA) terminated magnetic MSNs modified with Anti-S. aureus (Ab); MCM-41 SA20hp-MSNs: MCM-41 type MSNs functionalized with SA20hp; MSN-LU: MSNs modified with a lipidic bilayer surface shell and conjugated with UBI29–41; MSN@LL-(LL-37): MCM-41 type MSNs coated with a lipidic layer and conjugated with LL-37; M-PFPA-Tre: perfluorophenylazide-functionalized decorated with α,α-trehalose; Tre-HOMSNs: trehalose-functionalized hollow oblate MSNs; Arg-MSN: MCM-41 type MSNs functionalized with l-Arg; MSN@FA@CaP@FA: MSNs covered by double folic acid (FA) and calcium phosphate (CaP) layers; MCM-41 MSNs⊂VAN: MCM-41 type MSNs functionalized with vancomycin, MCM-41 OMV@MSN: MCM-41 type MSN core coated by an OMV as shell; ε-pLys-MSNs: MCM-41 type MSNs functionalized with pLys; MSN–AuNC@LYS: MSNs capped with LYS-functionalized gold nanoclusters. MCM-41 G3-MSNs: MCM-41 type MSNs functionalized with G3; MCM-41; and MCM-41 Mn+-G3-MSNs: MCM-41 type MSNs functionalized with G3 coordinated to Mn+ (Mn+ = Zn2+, Ag+).